Trial · NCT06120881
Precision Dosing of Metformin in Youth With T2D
NCT06120881, Early phase 1, Recruiting, University of California, San Francisco
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Precision Dosing of Metformin in Youth With T2D. Trials, record NCT06120881. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06120881
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Precision Dosing of Metformin in Youth With T2D
- NCT number
- NCT06120881
- Status
- Recruiting
- Phases
- Early phase 1
- Enrollment
- 20 participants, estimated
- Lead sponsor
- University of California, San Francisco
- Conditions
- Type 2 Diabetes
- Interventions
- Metformin
- First posted
- 2023-11-07
- Last updated
- 2025-12-23
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Acceptability of Higher Metformin Dose measured with the Acceptability of Intervention Measure (AIM) | Measured at 3 months | The perception that a higher dose of Metformin is agreeable or satisfactory measured with the 4-item Acceptability of Intervention Measure (AIM). A 4-item measure of perceived intervention acceptability. Items are measured on a 5-point Likert scale (Completely Disagree-Completely Agree). Score is calculated mean. The greater the score, the better the acceptability. |
| Primary | Feasibility of Higher Metformin Dose measured with the Feasibility of Intervention Measure (FIM) | Measured at 3 months | The extent to which a higher dose Metformin study can be successfully carried out measured with 4-item Feasibility of Intervention Measure (FIM). A 4-item instrument to assess perceived intervention feasibility. Items are measured on a 5-point Likert scale (Completely Disagree-Completely Agree). Score is calculated mean. The greater the score, the better the feasibility. |
| Secondary | Glycemic Change | Baseline (0) to 3 months | Change in serum HbA1C at 3 months adjusted for the baseline value youth with T2D on higher dose of metformin compared to standard dose |
| Secondary | Time in target glucose range | Baseline (0) to 3 months | Time spent in target glucose range of 70 to 180 mg/dL |
| Secondary | Time above high glucose range | Baseline (0) to 3 months | Percent of readings and time \>250 mg/dL |
| Secondary | Time above glucose range | Baseline (0) to 3 months | Percent of readings and time 181-250 mg/dL |
| Secondary | Time in glucose range | Baseline (0) to 3 months | Percent of readings and time 70-180 mg/dL |
| Secondary | Time below glucose range | Baseline (0) to 3 months | Percent of readings and time 54-69 mg/dL |
| Secondary | Time below low glucose range | Baseline (0) to 3 months | Percent of readings and time \<54 mg/dl |
| Secondary | Glucose management indicator | Baseline (0) to 3 months | Continuous glucose monitoring (CGM) metric that indicates average blood glucose. Glucose Management Indicator (GMI) approximates the laboratory A1C level expected based on average glucose measured using CGM values. Average glucose is derived from 14 or more days of CGM readings. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| K23DK120932 | A comprehensive approach to understanding the determinants of metformin pharmacokinetics and pharmacodynamics in youth with type 2 diabetes | SRINIVASAN, SHYLAJA | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2020 to 2024 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06120881
GET https://conductscience.org/api/trials/v1/NCT06120881/registered